Protalix BioTherapeutics, Inc. (PLX) Stock Overview
NYSE American · Healthcare · Biotechnology
✓ Sourced directly from Yahoo Finance · Checked for accuracy at every rebuild · Snapshot: 6 September 2026
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and…
Source: Yahoo Finance
Sector & Industry
Protalix BioTherapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry group. It is listed on the NYSE American exchange.
Protalix BioTherapeutics, Inc. at a Glance
| Company | Protalix BioTherapeutics, Inc. |
| Ticker | PLX |
| Exchange | NYSE American |
| Currency | USD |
| Price | $2.67 |
| Market cap | $215.13M |
| P/E ratio (trailing) | 11.61 |
| EPS (trailing) | $0.23 |
| 52-week high | $3.19 |
| 52-week low | $1.53 |
| Dividend yield | — |
| Ex-dividend date | — |
| Beta | 0.02 |
| Return on equity (ROE) | 31.24% |
| Debt-to-equity | 12.89% |
| Average volume | 681,712 |
| Shares outstanding | 80.57M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 226 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Evaluating pharma pipelines, devices and healthcare economics.
Check Price →Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Frequently Asked Questions
- What is Protalix BioTherapeutics, Inc.'s current P/E ratio?
- Protalix BioTherapeutics, Inc. (PLX) has a trailing P/E ratio of 11.61 as of our 6 September 2026 data snapshot. Learn what the P/E ratio means →
- What is Protalix BioTherapeutics, Inc.'s market capitalisation?
- Protalix BioTherapeutics, Inc.'s market cap is $215.13M based on our latest snapshot. See how it ranks by market cap →
- What is PLX's 52-week range?
- Over the past 52 weeks, PLX has traded between $1.53 and $3.19. What does the 52-week range mean? →
- How volatile is Protalix BioTherapeutics, Inc. compared to the market?
- Protalix BioTherapeutics, Inc. has a beta of 0.02, meaning it has historically moved less than the broader market. What does beta measure? →
- Does Protalix BioTherapeutics, Inc. pay a dividend?
- Protalix BioTherapeutics, Inc. does not currently pay a dividend according to our latest data.
- What exchange is PLX listed on?
- PLX is listed on the NYSE American. Browse all NYSE American-listed stocks →
- What sector is Protalix BioTherapeutics, Inc. in?
- Protalix BioTherapeutics, Inc. is classified in the Healthcare sector. Compare with Healthcare peers →
For compound interest, percentage change and other investing maths, try our free online calculators.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →Philip Fisher on what makes a business worth owning for the long term.
Check Price →